ArticleScientific reports2025
Total cholesterol/high-density lipoprotein cholesterol ratio is a candidate predictor of survival outcomes in patients with metastatic renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the predictive value of serum lipid levels, total cholesterol (TC)/ high-density lipoprotein cholesterol (HDL-C) ratio (TC/HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides in metastatic renal cell carcinoma (mRCC) treated with targeted therapy, sunitinib or pazopanib. A total of 111 mRCC patients were enrolled in this study. The correlation of lipid parameters with progression-free survival (PFS) and overall survival (OS) was performed with the Kaplan-Meier method and univariate and multivariate Cox regression models. The median PFS and OS of all patients were 12.2 months and 38.6 months, respectively. Receiver operating characteristic analysis showed that TC/HDL-C levels of 3.8 and 4 were optimal cut-off values in predicting PFS and OS, respectively. Patients with a high TC/HDL-C ratio had worse PFS and OS times than those with a low ratio (8.7 months vs. 19.3, p < 0.001; 24 months vs. 74.7 months, p = 0.003, respectively). Univariate analyses showed that among serum lipids, only the TC/ HDL-C ratio was associated with PFS (HR: 2.30, p < 0.001) and OS (HR:2.26, p = 0.004). When adjusted for the number of covariates, TC/ HDL-C was determined as an independent variable for the PFS (HR: 2.31, p < 0.001) and the OS (HR: 2.46, p = 0.003), respectively. The present study shows that TC/HDL-C ratio assessed in serum could be an important determinant for survival outcomes of mRCC patients treated with targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.